Intelligently
mining the market

Investors + news

We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe.

see our business strategy in action

Eagle Pharmaceuticals 2021 Annual Report

Investors Menu

Investors

Featured Press Release

•    Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •    Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY ® •  
See More
-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter -- -- ENA-001 works peripherally by inhibiting Big
See More
WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market opens.
See More

Upcoming Events & Presentations

Change % Volume Data as of 07/18/2022 12:34 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

In-Site
Communications, Inc.
Lisa M. Wilson,
212-452-2793

For all other media inquiries, please contact us.